nsc-366140 and Mediastinal-Neoplasms

nsc-366140 has been researched along with Mediastinal-Neoplasms* in 1 studies

Trials

1 trial(s) available for nsc-366140 and Mediastinal-Neoplasms

Article	Year
Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors. Investigational new drugs, 2000, Volume: 18, Issue:3 Thirteen patients with cisplatin-refractory germ cell tumors were treated on a Phase II trial with pyrazoloacridine. Pyrazoloacridine was given intravenously at 600 mg/m2 every three weeks. The median nadir leucocyte count was 2.5 cells/mm3, hemoglobin was 10.8 g/dl, and platelet count was 126,000 cells/m3. None of the thirteen evaluable patients achieved a major response. Pyrazoloacridine is not efficacious in the treatment of cisplatin-refractory germ cell tumors. Topics: Acridines; Adult; Antineoplastic Agents; Cisplatin; Female; Germinoma; Humans; Male; Mediastinal Neoplasms; Middle Aged; Pyrazoles; Testicular Neoplasms	2000

Article

Year

Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors.

Investigational new drugs, 2000, Volume: 18, Issue:3

Thirteen patients with cisplatin-refractory germ cell tumors were treated on a Phase II trial with pyrazoloacridine. Pyrazoloacridine was given intravenously at 600 mg/m2 every three weeks. The median nadir leucocyte count was 2.5 cells/mm3, hemoglobin was 10.8 g/dl, and platelet count was 126,000 cells/m3. None of the thirteen evaluable patients achieved a major response. Pyrazoloacridine is not efficacious in the treatment of cisplatin-refractory germ cell tumors.

Topics: Acridines; Adult; Antineoplastic Agents; Cisplatin; Female; Germinoma; Humans; Male; Mediastinal Neoplasms; Middle Aged; Pyrazoles; Testicular Neoplasms

2000